Human Gene Therapy Program

Back To Journal

Author Services

Human Gene Therapy is pleased to provide a full range of robust Author Services. Click links below for program details.

Manuscript Submission Guidelines

Human Gene Therapy (HGT), celebrating its 25th anniversary, has published over 4,000 papers, reviews, and editorials. Over the last 2 years we expanded the Human Gene Therapy portfolio to include Human Gene Therapy Methods and Human Gene Therapy Clinical Development. Submit your research today and join the growing HGT community!

•Manuscript Submission Guidelines for Human Gene Therapy

To access the guidelines for other Mary Ann Liebert, Inc. journals, browse our collection and select your journal. Roll over the “For Authors” button located on the top right of the journal page (below the search tool) and select "Manuscript Submission."

Guidelines for Writing a Research Paper

As a resource for new and first-time submitters, we provide general guidelines for writing a quality research paper, translated into 10 languages. Authors referring to these basic recommendations should also consult the specific manuscript instructions for the Journal to which they will be contributing for detailed submission information.

Basic Manuscript Submission Guidelines (10 languages)

Research Writing Guidelines
White Paper:
PR for MDs & PhDs: Gaining Exposure for Your Academic Articles

Women and men of academic letters, it’s time to learn how to self-promote! Today every writer’s primary resource for exposure is the Internet. This downloadable white paper provides you with strategic guidelines, tips, and tools to ensure maximum visibility of your research and enhance your professional profile.

Download the white paper

Author Benefit Programs


AuthorCite® is a dynamic author services platform that delivers a 360-degree view of your article from submission to publication to market impact, with comprehensive tools to take control of how your work is read, shared, and measured.

Learn more about AuthorCite®

AuthorCite Logo
*Exclusively licensed by Mary Ann Liebert Inc., publishers
Liebert Open Access Option

The Liebert Open Access Option program provides immediate free online posting of your article upon publication without an embargo period, for a flat one-time fee. This fee also makes the article free in perpetuity on the site. If you've received NIH funding we will also immediately deposit your paper to PubMed Central (PMC).
Contact for specific questions regarding our Open Access policy, and pricing.

Learn more about Liebert Open Access Option

Liebert Open Access Logo
Liebert Open Access Icon

Our Policies

NIH Public Access Policy

In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after publication. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

HHMI and Wellcome Trust

Authors Funded by HHMI and Wellcome Trust should follow the instructions for Liebert Open Option above. Contact for specific questions regarding our HHMI and Wellcome Trust policies.

Learn more about our HHMI and Wellcome Trust Policy


Mary Ann Liebert, Inc. is a "blue" publisher, as we allow self-archiving of post-print (i.e. final draft post-refereeing) or publisher's version/PDF.

Learn more about our Self-Archiving Policy